Follow-up was measured from the date of diagnosis to the date of last news for live patients. Data concerning patients without disease progression or death at last follow-up were censored. Survival curves were selleck compound estimated using the Kaplan-Meier method, and compared with the log-rank test. The prognostic impact of above-cited factors and chemotherapy regimen was assessed by the Cox regression
method both in univariate and multivariate analysis. Multivariate analyses only included variables with p-value lower than 5% in univariate analysis. All statistical tests were two-sided at the 5% level of significance. Statistical analyses were performed using SPSS software (version 16.0). Results Patients and treatment One hundred sixty-three patients with advanced ovarian carcinomas treated at our institution between April 1995 and July 2009 were included in this study. Tumor characteristics are listed
in Table 1. Median age at diagnosis was 54 years (standard deviation, 8.7 years) and 68% were older than 50 years. Fifty three percent were grade II serous tumors. Complete cytoreductive surgery could not be achieved for 41% of patients. Seventy percent presented no clinical residual disease after conventional treatment including surgery and chemotherapy. All patients received a platinum/taxane-based chemotherapy. Ninety percent of patients received carboplatin, 10% cisplatin, 79% H 89 concentration Paclitaxel and 21% docetaxel. Carboplatin was given every three weeks, according to the Calvert’s formula with an area under curve of 6 before and 5 after January 2005. Cisplatin was given every three weeks
at a dose of 75 mg/m2. Paclitaxel was Doramapimod clinical trial administered every three weeks at the dose of 175 mg/m2 until 2008, and then weekly at the dose of 80 mg/m2. Docetaxel was given with a 3-weeks frequency, at the dose of 75 mg/m2. Patients received a median of 6 cycles, with a minimum of 1, and a maximum of 8 cycles. Table 1 Clinicopathological features of advanced ovarian carcinomas with and without high-dose chemotherapy CCA HDC p -value Odd or Hazard Ratio (95CI) N N (%) N (%) 103 60 Follow-up (median, months) 163 46.7 48.2 0.08*** Median Age (years) 163 56,0 53,0 0 09*** Age 163 0.73**** 1.15 [0.55-2.45] ≤50y 34 (33) 18 (30) >50y 69 (67) 42 however (70) OMS 117 0.17**** 0.35 [0.06-1.37] 0-1 63 (81) 36 (92) 2-3 15 (19) 3 (8) FIGO 163 0.33**** 1.47 [0.63-3.39] IIIc 84 (82) 45 (75) IV 19 (18) 15 (25) Histological subtype 163 0.62**** 0.82 [0.40-1.65] Serous 62 (60) 39 (65) Others 41 (40) 21 (35) Grade 98 0.01**** 0.32 [0.12-0.81] 1-2 19 (31) 21 (58) 3 43 (69) 15 (42) Cytoreductive surgery 160 Complete 56 (56) 40 (67) 0.24**** 0.64 [0.31-1.30] residual disease 44 (44) 20 (33) Clinical complete response* 161 Yes 63 (62) 50 (83) 0.007**** 0.33 [0.14-0.